Genprex, Inc. (GNPX) Stock Price, News, Quote & History - Yahoo Finance (2025)

Table of Contents

Full Time Employees Fiscal Year Ends Sector Industry Recent News: GNPX Performance Overview: GNPX YTD Return 1-Year Return 3-Year Return 5-Year Return Compare To: GNPX Statistics: GNPX Valuation Measures Financial Highlights Research Analysis: GNPX Company Insights: GNPX Research Reports: GNPX People Also Watch FAQs References

0&&s)if(o){var r,a=(r=e.newCount)>99;s.textContent=a?"99+":r+"",null===(t=s.parentElement)||void 0===t||t.classList.add(zt)}else s.style.display="block"},m=function(){d.refreshPanel().then(h).then(ee).catch((function(){}))};e.addEventListener("close-all-menus",(function(){Le(c)||u()})),c&&(m(),setInterval((function(){m()}),3e5),o?l&&l.addEventListener("mouseenter",(function(){p(),null==t||t.show()})):c.addEventListener("mouseenter",(function(){p(),null==t||t.show()})),c.addEventListener("mouseleave",(function(){u(),null==t||t.hide()}))),e.addElementListener(i,"click",(function(){Q("ybar","notification","",{elm:"btn",elmt:"block"===(null==s?void 0:s.style.display)?"newalert":"",subsec:"notification",itc:"1"})})),r&&Ee(e,r,"ybar","notification",{elm:"expand",subsec:"notifications",itc:"2"}),e.addElementListener(a,"focusin",(function(){i&&(i.checked=!0),null==a||a.classList.add("ybarMenuOpen")})),e.addElementListener(a,"focusout",u),e.addElementListener(n.tooltipContainer,"focusin",(function(){null==t||t.show()})),e.addElementListener(n.tooltipContainer,"focusout",(function(){null==t||t.hide()}));var f=e.getConfig().device,v=document.getElementById("ybar");v&&v.classList.contains("ybar-ytheme-crunch")&&(eo=0);var y=new RegExp("[?&]notifications=1(&|#|$)");"desktop"===f&&i&&y.test(window.location.search)&&(i.checked=!0)};ye("ybar-mod-notification",(function(e){var n={isUH3:"crunch"===e.getConfig().ytheme,notifContainer:document.getElementById("notification-container"),notifBadge:document.getElementById("notif-badge"),notifMenu:document.getElementById("ybarNotificationMenu"),notifMenuOpener:document.querySelector("#ybarNotificationMenu + label"),notifDropdown:document.getElementById("notifDropdownContainer"),tooltipContainer:document.querySelector(".".concat(Gt)),notifLabel:document.querySelector(".".concat(Wt))};to(e,n)}))}()}};

NasdaqCM - Delayed Quote • USD

Compare

0.8502 -0.4198 (-33.06%)

At close: 4:00 PM EDT

0.8623 +0.01 (+1.42%)

After hours: 6:59 PM EDT

Key Events

Line

Candle

Baseline

Mountain

Bar

Advanced Chart

Loading Chart for GNPX

9/21 12:03 PM

DELL

Date
Close
Open
High
Low
Volume

Previous Close 1.2700
Open 1.0900
Bid --
Ask --
Day's Range 0.8000 - 1.1400
52 Week Range 0.8000 - 25.3600
Volume 3,269,232
Avg. Volume 103,261
Market Cap (intraday) 1.784M
Beta (5Y Monthly) -0.51
PE Ratio (TTM) --
EPS (TTM) -15.6000
Earnings Date Nov 12, 2024 - Nov 18, 2024
Forward Dividend & Yield --
Ex-Dividend Date --
1y Target Est 165.00

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC. Its three lung cancer clinical programs have received a Fast Track Designation from the FDA for the treatment of that patient population, and SCLC program has received an FDA Orphan Drug Designation. The company's diabetes gene therapy comprises of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, its GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which produce insulin but distinct enough from beta cells to evade the body's immune system; and GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

www.genprex.com

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

More about Genprex, Inc.

Recent News: GNPX

All SEC Filings

Corporate Changes & Voting Matters

Periodic Financial Reports

Proxy Statements

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

GNPXGenprex, Inc.

0.8502

-33.06%

Mkt Cap 1.784M

Industry Biotechnology

SKYESkye Bioscience, Inc.

4.1500

-9.78%

Mkt Cap 125.904M

Industry Biotechnology

RVPHReviva Pharmaceuticals Holdings, Inc.

0.6895

-15.71%

Mkt Cap 20.559M

Industry Biotechnology

KAKineta, Inc.

0.6050

-1.55%

Mkt Cap 7.414M

Industry Biotechnology

ZVSAZyVersa Therapeutics, Inc.

2.9200

+2.46%

Mkt Cap 2.438M

Industry Biotechnology

BNOXBionomics Limited

0.6050

-1.16%

Mkt Cap 8.015M

Industry Biotechnology

DAREDaré Bioscience, Inc.

4.2000

+20.00%

Mkt Cap 35.383M

Industry Biotechnology

KTTAPasithea Therapeutics Corp.

4.8500

+1.25%

Mkt Cap 5.06M

Industry Biotechnology

CRDFCardiff Oncology, Inc.

2.2500

-0.44%

Mkt Cap 104.737M

Industry Biotechnology

ATXIAvenue Therapeutics, Inc.

2.4999

+0.40%

Mkt Cap 2.352M

Industry Biotechnology

IMRNImmuron Limited

2.5450

-2.12%

Mkt Cap 15.945M

Industry Biotechnology

Statistics: GNPX

Valuation Measures

Annual

As of 8/12/2024

Market Cap

2.64M
Enterprise Value

185.34k
Trailing P/E

--
Forward P/E

--
PEG Ratio (5yr expected)

--
Price/Sales (ttm)

--
Price/Book (mrq)

0.61
Enterprise Value/Revenue

--
Enterprise Value/EBITDA

0.18

Financial Highlights

Profitability and Income Statement

Profit Margin

0.00%
Return on Assets (ttm)

-145.94%
Return on Equity (ttm)

-318.88%
Revenue (ttm)

--
Net Income Avi to Common (ttm)

-26.14M
Diluted EPS (ttm)

-15.6000

Balance Sheet and Cash Flow

Total Cash (mrq)

2.46M
Total Debt/Equity (mrq)

--
Levered Free Cash Flow (ttm)

-12.45M

Research Analysis: GNPX

Company Insights: GNPX

Research Reports: GNPX

People Also Watch

DARE Daré Bioscience, Inc.

4.2000

+20.00%

CODX Co-Diagnostics, Inc.

1.1700

+1.74%

AIM AIM ImmunoTech Inc.

0.2699

+1.47%

COCP Cocrystal Pharma, Inc.

1.9000

+7.95%

AYTU Aytu BioPharma, Inc.

2.4175

+1.15%

OPGN OpGen, Inc.

2.1000

-2.55%

VTVT vTv Therapeutics Inc.

13.18

+1.00%

AGRX Agile Therapeutics, Inc.

1.4600

0.00%

NNVC NanoViricides, Inc.

1.7400

-1.69%

PIXY ShiftPixy, Inc.

1.0600

+3.92%

CTXR Citius Pharmaceuticals, Inc.

0.6104

-11.69%

CAPR Capricor Therapeutics, Inc.

3.9250

+0.13%

CLSD Clearside Biomedical, Inc.

1.0650

-0.47%

HOTH Hoth Therapeutics, Inc.

0.6064

-2.82%

BSGM BioSig Technologies, Inc.

0.5200

+15.56%

VBIV VBI Vaccines Inc.

0.0653

0.00%

Genprex, Inc. (GNPX) Stock Price, News, Quote & History - Yahoo Finance (2025)

FAQs

Is GNPx a good stock to buy? ›

The consensus among 1 Wall Street analyst covering (NASDAQ: GNPX) stock is to Buy GNPX stock.

Symbol	Price	Change
INTC Intel Corporation	20.91 +1.25 (+6.36%)	+1.25
PLTR Palantir Technologies Inc.	36.31 +0.72 (+2.02%)	+0.72
TSLA Tesla, Inc.	226.78 -3.51 (-1.52%)	-3.51
AAPL Apple Inc.	216.32 -6.18 (-2.78%)	-6.18

Stock	30-year total return*	Growth of $10,000
Apple Inc. (AAPL)	88,807%	$8,890,734
Netflix Inc. (NFLX)	58,273%**	$5,837,319
Pool Corp. (POOL)	56,328%**	$5,642,835
Axon Enterprise Inc. (AXON)	56,082%**	$5,618,189

What is the average return of the S&P 500 last 30 years? ›

The average yearly return of the S&P 500 is 10.733% over the last 30 years, as of the end of July 2024. This assumes dividends are reinvested. Adjusted for inflation, the 30-year average stock market return (including dividends) is 7.998%.

Show Me More ›

What is the S&P 500 monthly return with dividends? ›

S&P 500 Monthly Total Return is at 2.43%, compared to 1.22% last month and -1.59% last year. This is higher than the long term average of 0.73%. The S&P 500 Monthly Total Return is the investment return received each month, including dividends, when holding the S&P 500 index.

Get More Info ›

Is O Reilly a good stock? ›

O'Reilly Auto's analyst rating consensus is a Strong Buy. This is based on the ratings of 14 Wall Streets Analysts.

Tell Me More ›

Should I buy NBIX stock? ›

Neurocrine has a consensus rating of Strong Buy which is based on 17 buy ratings, 5 hold ratings and 0 sell ratings.

Get More Info Here ›

What is the target price for MGNX stock? ›

MGNX Stock 12 Month Forecast

Based on 12 Wall Street analysts offering 12 month price targets for MacroGenics in the last 3 months. The average price target is $7.25 with a high forecast of $14.00 and a low forecast of $4.00. The average price target represents a 95.95% change from the last price of $3.70.

Discover More ›

Should you buy GE stock? ›

GE Aerospace has a consensus rating of Strong Buy which is based on 12 buy ratings, 0 hold ratings and 0 sell ratings. The average price target for GE Aerospace is $198.58. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.

Show Me More ›